The treatment of acute and chronic severe pain remains a common major challenge faced by clinicians working with the general population, and even after the application of recent advances to treatments, there may still continue to be manifestations of adverse effects.
INTRODUCTION
Pharmaceutical innovation is gradual and can develop in different ways, including through a new drug, a new indication for an existing drug, or a new pharmaceutical formulation to improve the pharmacological profile [1] . Another option for pharmaceutical innovation is a combined treatment with two or more drugs with complementary mechanisms of action, which in fixed-dose combinations can be available in a single tablet [2] .
In the area of pain, although there is no "perfect analgesic", scientists can continue to search for compounds with qualities that can approach the "perfect analgesic" by improving the pharmacokinetic and pharmacodynamic aspects of analgesics.
For many years, researchers have been developing new pharmaceutical strategies to help improve the effectiveness of analgesics and prevent or decrease adverse effects by combining these analgesics with a second agent, which may or may not be another analgesic [3] . This "second non-opioid agent" may be referred to as a "co-analgesic" or "adjuvant analgesic".
Drug combinations in pain management have been developed for different therapeutic purposes, which can be classified into six categories [3] : 1) to prolong analgesic duration; 2) to enhance or optimize analgesic efficacy (e.g., analgesic synergy); 3) to prevent or reduce adverse effects; 4) to alleviate opioid effects which are not beneficial (or to spinal CGRP, in response to a sustained opioid exposure, and finally contributes to the initiation and maintenance of morphine-induced tolerance [20] .
The substance P (SP) plays an important role in spinal nociceptive processing and as a regulatory effector of opioiddependent analgesic processes [24] , with increased spinal activity of SP together with CGRP contributing to the development of opioid tolerance-dependence [25] .
Prostaglandins (PGs) (such as prostaglandin E2) are lipid products generated from arachidonic acid by the action of cyclooxygenase (COX) enzymes (COX-1 and COX-2). The synthesis and release of prostaglandins from astrocytes [26, 27] and neurons [28] in the spinal cord can be induced by the activation of NMDA receptors [29, 30] and NK-1 receptors. Moreover, these prostaglandins act retrogradely (positive feedback) on primary afferent terminals to stimulate further the release of excitatory amino acids (l-glutamate) and neuropeptides (SP) [31 -33] . Experimental studies have shown that the increase of the positive feedback between neuropeptides and prostaglandins in the dorsal horn, under the influence of chronic morphine, may be connected to the induction of the opioid tolerant-dependent state [20] .
The spinal lipoxygenase (LOX) metabolites from arachidonic acid, such as leukotriene B4 (LTB4), play a role in the induction of hyperalgesia and development of opioid analgesic tolerance. Also, chronic morphine exposure probably increases activity in the LOX cascade at the spinal level [34] .
Morphine toxicity occurs by the accumulation of its metabolites without analgesic potency but has an important neurotoxic effect [21] . In man, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) are the major metabolites of morphine [35] . Although M6G contributes to the analgesic effect of morphine, the M3G metabolite produces neurotoxicity [21, 36] . However, toxicity can also be produced by the neurotoxic action toxicity of the highdose opioid itself.
The adverse effects of morphine can be divided into dose-dependent and dose-independent effects, with the most common dose-dependent ones being nausea, vomiting, and drowsiness, which always appear after a certain dose and disappear within a few days or on decreasing the dosage. The most frequent dose-independent adverse effects include constipation, and hallucinations, and these appear regardless of the dose administered and do not disappear as there is no phenomenon of tolerance. Respiratory depression is certainly the most serious adverse effect. However, this side effect is very rare, and can be treated with naloxone and minimized by careful titration [37] . Common side effects include nausea and vomiting, which occur in one to two thirds of patients taking opioids [38] . These are particularly common complications at the start of treatment with opioids, but usually disappear during the first week of treatment.
Although the above side effects are still not entirely understood, multiple and complex mechanisms are likely to be involved in both the peripheral and central nervous system, including (I) stimulation of the vestibular apparatus (with symptoms often including vertigo and worsening with motion), (II) direct effects on the chemoreceptor trigger zone, and (III) delayed gastric emptying (with symptoms of early satiety and bloating, and also worsening postprandially) [39] . Antiemetic drugs used to suppress emesis or the vomiting associated with the clinical use of morphine include the following: haloperidol (Dopamine 2 receptor antagonist), promethazine (Histamine 1 receptor antagonist), naloxone (mu/delta opioid receptors antagonist), ondansetron (5-HT 3 receptor antagonist), scopolamine (Muscarinic1 receptor antagonist), aprepitant (Tachykinin NK1 receptor antagonist) and dronabinol (cannabinoid CB1 agonist) [39] .
The sedative effects of opioids are well known in patients not previously treated with opioids [40] . Sedation and cognitive impairment occur early in treatment, with tolerance to these effects taking place when a stable dose is reached [41] . Morphine causes sedation and somnolence, possibly due to the anticholinergic activity of opioids, with drowsiness also being common at the beginning of treatment and consequently being a risk for patients who drive [42] . These adverse effects can be alleviated by reducing the dose through opioid rotation, and also by the use of psychostimulants such as methylphenidate [43 -46] to improve subjective drowsiness and psychomotor performance scores [47] . Constipation occurs in 40-95% of opioid-treated patients, and can even happen after a single dose of morphine [48] . As this can decrease the quality of life and work productivity of patients, in cases of severe constipation patients should reduce the opioid dose, resulting in decreased analgesia. However, constipation is unlikely to improve over time, and therefore it should be monitored during treatment with morphine [49] . This persistent effect often requires a simultaneous additional treatment [41, 42] , with several studies having suggested that mu-opioid receptors play a key role in opioid-induced constipation [50] . Related to this, in the treatment of opioid-induced constipation, recent positive clinical efficacy data have been obtained with two peripherally acting antagonists, methylnaltrexone and alvimopan, of the mu-opioid receptor [51] . Finally, pruritus or severe itching of the skin occurs frequently with opioid use and is difficult to treat. Although antihistamines have been found to be useful for counteracting this itching, this adverse effect of opioids can often lead to treatment discontinuation [52] .
STRATEGIES TO MANAGE THE ADVERSE EFFECTS OF MORPHINE
Effective pain management with opioids, such as morphine remains a major clinical challenge and can fail due to: (1) inadequate analgesia, (2) excessive adverse effects, or (3) a combination of both these factors [53, 54] , with multiple approaches having been attempted to address this problem using different pharmacological options.
For several years, researchers have been developing new pharmaceutical strategies to improve the effectiveness of analgesics and to prevent or at least reduce the severity of adverse effects by combining an analgesic with a second agent, which may or may not be an analgesic [3] . Related to this, a second "non-opioid agent" may be referred to as a "coanalgesic" or "adjuvant analgesic". This incorporation of adjuncts in opioid therapy can help to reduce pain and improve the quality of life in sufferers.
Adjuncts to opioid therapy include nonsteroidal anti-inflammatory drugs (e.g., ibuprofen) [55] , acetaminophen [56] , antiarrhythmics, anticonvulsants [57] , antidepressants (such as desipramine) [58] , antipsychotics, baclofen, benzodiazepines, capsaicin, calcium channel blockers, clonidine hydrochloride [59] , central nervous system stimulants, corticosteroids, local anesthetics, N-methyl-D-aspartate receptor antagonists and scopolamine [60, 61] . Of these, some (e.g., acetaminophen) are currently routinely used, whereas others (e.g., nifedipine [calcium channel blocker]) are only administered on a limited basis. However, one problem with the use of many adjuvant analgesics is that they have the potential to cause side effects which may be additive to the opioid adverse effects, thus further complicating treatment [4] .
Omega-3 Fatty Acids Combined With Morphine
Pain in physiological and pathological conditions can be treated with medication, as well as by nutritional strategies or using dietary supplements [62] . It is well known that certain food components (administered in foods or in their pure forms) have been shown to play a role as medicaments. Thus, dietary modulation of an inflammatory reaction may be a therapeutic option for treating a variety of diseases [63] . In fact, the omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in the form of fish oil are probably the best known examples of how diet can reduce inflammation [64] .
The human body can synthesize numerous fatty acids referred to as non essential, while other fatty acids called essential fatty acids (EFAs) should be incorporated into the diet because they cannot be synthesized by humans [65] . These include Linoleic acid (LA), an omega-6 polyunsaturated fatty acid (omega-6 PUFA) and alpha-linolenic acid (ALA), an omega-3 PUFA.
The parent 18-carbon fatty acid, alpha--linolenic acid (ALA; 18:3n−3) is present in various vegetable oils, such as flaxseed, linseed, canola and soy oils, and ALA can be metabolized to other more unsaturated long-chain members of the omega-3 PUFAs by the insertion of additional double bonds during consecutive elongation and desaturation. In this way, it can be metabolically converted to various omega-3 PUFAs, including eicosapentaenoic acid (EPA; 20:5n−3) and docosahexaenoic acid (DHA; 22:6n−3). This metabolic conversion of ALA occurs primarily in the endoplasmic reticulum in the liver, and involves a series of elongation enzymes that sequentially add 2-carbon units to the fatty acid backbone and desaturation enzymes that insert double bonds into the molecules [66] .
The final conversion of ALA to DHA requires a translocation to the peroxisome for a β-oxidation reaction, with the capacity to generate DHA from ALA being higher in women than men [67] . Moreover, several studies have shown that ≥15-35% of dietary ALA is rapidly catabolized to carbon dioxide for energy [67 -71] . In healthy young men, approximately 8% of dietary ALA is converted to EPA and 0-4% is converted to DHA [72] , whereas in healthy young women, approximately 21% of dietary ALA is converted to EPA and 9% is converted to DHA [68] . Finally, DHA can be retroconverted to EPA at a low basal rate and following supplementation [72 -75] (Fig. 1) .
The two most important omega-3 PUFAs involved with human physiology and pharmacology effects are DHA and EPA, but due to the low conversion efficiency from ALA it is recommended that EPA and DHA are obtained from additional sources, such as fish oil supplements.
Linoleic acid (LA, C18:2n-6) can be metabolized to other more unsaturated long-chain members of the n-6 family by the insertion of additional double bonds during consecutive elongation and desaturation mechanisms. In this way, LA is converted to Arachidonic acid (AA, 20:4n-6) via γ-linolenic acid (GLA, 18:3n-6) and dihomo-γ-linolenic acid (DGLA, 20:3n-6) (Fig. 1) .
As the same enzymes involved in omega-3 PUFA synthesis are responsible for the conversion of omega-6 PUFA LA to AA, background diet can influence the conversion of these fatty acids. Nevertheless, the regulation of desaturation and the elongation of omega-3 and omega-6 PUFAs are still poorly understood, although they are known to involve competitive substrates, enzyme regulation, and nutritional, hormonal, physiological and pathological factors [76] .
Since ALA and LA are metabolized by the same set of enzymes, a natural competition exists between these two fatty acids, whereby delta-5-desaturase and delta-6-desaturase will exhibit an affinity to metabolize omega-3 PUFAs over omega-6 PUFAs, provided that they exist at a ratio of 1: 1-4. However, the higher consumption of LA in the typical western diet causes an increase in the preference of these enzymes to metabolize omega-6 PUFAs, leading to AA synthesis, despite the fact that these enzymes show a higher affinity for n-3 PUFAs [77] for ratios of 15:1 to 16.7:1 [78] . Excessive amounts of omega-6 PUFAs promote the pathogenesis of many diseases, including cardiovascular disease, chronic inflammatory diseases such as nonalcoholic fatty liver disease, obesity, inflammatory bowel disease, rheumatoid arthritis, Alzheimer's disease, cancer and autoimmune diseases [79, 80] . However, supplementation of the diet with fish oil (EPA and DHA) has been shown to correct this imbalance by partially replacing AA in the cell membranes of platelets, erythrocytes, neutrophils, monocytes, and hepatocytes, where AA is usually found at high proportions [79, 80] .
Omega-3 and omega-6 PUFAs have opposite effects, and the balance between them is critical as diet plays an important role in determining the body's inflammation status. Whereas omega-6 PUFAs derived signaling molecules are inflammatory, the omega-3 PUFA derived signaling molecules are anti-inflammatory [81] , with EPA and DHA, for example, being precursors of potent anti-inflammatory lipid mediators such as resolvins and protectins [82] .
In both preclinical and clinical studies, omega-3 PUFAs have been shown to contribute to the reduction of inflammatory pain in different situations, such as inflammatory bowel disease [83] , chronic headaches [84] , knee osteoarthritis [85, 86] , inflammatory joint pain [81] , neck or back pain (discogenic pain) [87] , rheumatoid arthritis [88 -96] neuropathic pain [82, 97] , musculoskeletal injury [98] and dysmenorrhea [99] . In these clinical studies, different effective doses of fish oils (DHA and EPA) and treatment times were utilized Table (1) , with other preclinical studies also having revealed the antinociceptive effect of different types of omega-3 PUFAs [100 -102] . Recent pre-clinical studies in our laboratory have demonstrated that acute treatment with morphine following 16 days of omega-3 PUFAs (DHA and EPA) had a greater antinociceptive effect than morphine alone at the same dose, thus revealing an additive effect. However, omega-3 PUFA chronic treatment with morphine attenuated or blocked the development of tolerance to morphine after 16 or 30 days of treatment, respectively [76] .
Morphine is known to produce a decrease in body weight in rats [103] , but omega-3 PUFA chronic treatment with morphine can reduce this effect. Moreover, morphine reduces the gastrointestinal transit, whereas co-administration of omega-3 PUFAs with morphine blocks this morphine effect [104] .
We recently demonstrated that naloxone, a pure opioid antagonist, blocks the analgesia produced by omega-3 PUFAs alone or in co-administration of omega-3 PUFAs with morphine, suggesting that the analgesic activity of both might be exerted via a mechanism related to the opioid system [104] .
Furthermore, a new pharmaceutical mixture (omega-3 PUFA/morphine) obtained by dissolving morphine in salmon oil allowed the concomitant oral administration of both components, which showed analgesic activity with a subtherapeutic dose of morphine, lower side-effects associated with morphine treatment, and also prevented or least reduced the possibility of developing tolerance to the analgesic effect of morphine [104, 105] The exact mechanism by which omega-3 PUFAs reduce pain is not fully understood, but some reports about the mechanisms underlying the antinociceptive effect of omega-3 PUFAs have suggested that this pain reduction occurs through:
Inhibition of the production of proinflammatory eicosanoids and cytokines via the suppression of the 1.
arachidonic acid cascade [106 -109] . Analgesic action of the omega-3 PUFA -derived mediators, with recent studies having demonstrated that EPA 2.
and DHA act/serve as precursors for the E-series (RvE1, RvE2) and D-series (RvD1, RvD2) resolvins, respectively, which are potent analgesics [110 -114] . Regulatory action on both the peripheral and central transient receptor potential of vanilloid 1 (TRPV1) and 3.
acid-sensing ion channels (ASICs) for omega-3 PUFAs [102, 115] .
The modulation of the TRPV1 receptor function produces pain relief at the level of the primary sensory neuron. While TRPV1 receptor activation by prolonged application of an agonist results in the release of central transmitters (glutamate and substance P) from nociceptive afferents and consequently a desensitization to generate action potentials, a TRPV1 receptor antagonist blocks the ion channel pore [116] . Interestingly, whereas DHA is a potent TRPV1 agonist, EPA inhibits the activation of this cation channel by various agonists [115] .
The acid-sensing ion channels (ASICs), such as ASIC1a, ASIC1b and ASIC3, have been implicated in pain perception. ASICs are excitatory cation channels directly gated by extracellular protons of many painful conditions [117, 118] . However, recent studies have demonstrated that omega-3 PUFAs decrease the mRNA expression of ASIC1a, ASIC3 and TRPV1, suggesting a reduced inflammatory status, which may be the reason for the increased pain threshold [102] .
Increasing the release of β-endorphin. Nakamoto et al. [119] demonstrated that the DHA facilitated the release 1.
of β-endorphin, mediated (at least in part) through GPR40 signaling, and finally the stimulation of μ-and δ-opioid receptors induced antinociception [120] . Analgesic action of the epoxidized metabolites derived from omega-3 PUFAs DHA (epoxydocosapentaenoic 2.
acid, EDP) and EPA (epoxyeicosatetraenoic acid, EEQ), which are metabolized by cytochrome P450. The metabolites produce epoxy docosapentaenoic acid and epoxy eicosatetraenoic acid, and have a direct antinociceptive role [121, 122] (Fig. 2) . 
CONCLUSION
The findings discussed in this review indicate a role for omega-3 PUFAs as adjuncts to morphine in pain treatment, which might help to increase analgesia and decrease adverse effects, as well as lead to a reduction of tolerance to analgesic effects. 
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